

# Exactus, Inc.

08:00 28 Aug 2019

## Exactus on track to produce more than 20,000 pounds of premium hemp flower, begins taking orders

Exactus Inc (OTCMKTS:EXDI) announced Wednesday that it is on track to exceed its initial estimates of 20,000 pounds of top flower and will begin taking orders.

The Florida-based CBD healthcare company revealed it has made significant progress on the two 100-acre industrial hemp farms it owns located in Southwest Oregon.

In a statement, Exactus CEO Emiliano Aloï said: "Our farming efforts and our team's relentless pursuit of quality are beginning to show. With the near completion of our on-site drying and packaging infrastructure, we will be able to deliver premium hemp flower products straight from the farm."

### READ: Exactus executes its growth strategy following Oregon hemp farm acquisition

The company said compliance tests performed on samples taken from all the fields by personnel from the Oregon Department of Agriculture (ODA) achieved a 100% pass rate.

"It was a good day, our crop is healthy and every test returned by the ODA passed with flying colors. Our highest THC read was 0.1%, which is 1/3rd of the compliance limits set by the US Agricultural Improvement Act of 2018," noted Shea McInvale, manager of Exactus One World.

The CBD producer said it will begin harvesting on September 15 and will continue to harvest top flower through November.

As a result, delivery of 2019 flower products will begin in October following drying, processing and packaging.

### Flowers being served up

Exactus also offered a glimpse into the strains of top flower it was serving up for distribution:

- Sover Haze, which is known for its open flower structure, resulting in record-setting resin content.
- Special Sauce, the flagship line, contains exotic astringent berry smells, beautiful pink pistils, and some of the highest oil returns of any industrial hemp. The flowers are smaller than others but end up very dense and coated in glistening resin. This is a top seller in the international trimmed flower market and peerless for full spectrum oil extraction.
- Lifter which carries a farnesene dominant terpene profile with a flavor very sought after by consumers.
- Hawaiian Haze, which is a cross-breed between a specially selected Neville's Haze male specimen and the popular ACDC. It brings farmers equatorially inspired, long season flavor with large yielding, modern hybrid flower structures.

**Price:** 0.065

**Market Cap:** \$3.46 m

### 1 Year Share Price Graph



December 2019 May 2020 November 20

### Share Information

**Code:** EXDI

**Listing:** OTCQB

**52 week High Low**  
0.655 0.04

**Sector:** Pharma & Biotech

**Website:** www.exactusinc.com

### Company Synopsis:

*Exactus, Inc. , is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0. 3 percent or less. THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics.*

action@proactiveinvestors.com

This has been among the most popular flower products since its first field trials in 2017.

- Sour Space Candy has the strongest stalk of any plant and sports a unique, terpinolene-forward flavor. This variety yields a unique flavor profile reminiscent of sour candy and growers are rewarded with full, golf ball-sized flowers that stay intact, even when subjected to machine trimming.

Exactus is building its presence in the US through a deal with Green Goddess Extracts, a highly regarded Florida contract manufacturer and formulator of hemp and vape products which distributes a premium line of high-quality hemp products sold through distributors and online.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Exactus, Inc. named herein, including the promotion by the Company of Exactus, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).